153 related articles for article (PubMed ID: 38676720)
21. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
[TBL] [Abstract][Full Text] [Related]
22. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.
Roder C; Bisdas S; Ebner FH; Honegger J; Naegele T; Ernemann U; Tatagiba M
Eur J Surg Oncol; 2014 Mar; 40(3):297-304. PubMed ID: 24411704
[TBL] [Abstract][Full Text] [Related]
23. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
24. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
[TBL] [Abstract][Full Text] [Related]
25. Relationship between tumor cell infiltration and 5-aminolevulinic acid fluorescence signals after resection of MR-enhancing lesions and its prognostic significance in glioblastoma.
Kim J-; Jung T-; Jung S; Kim I-; Jang W-; Moon K-; Kim S-; Kim J-; Lee K-
Clin Transl Oncol; 2021 Mar; 23(3):459-467. PubMed ID: 32617871
[TBL] [Abstract][Full Text] [Related]
26. Positive influence of partial resection on overall survival of patients with overlapping glioblastomas.
Quick-Weller J; Tritt S; Baumgarten P; Konczalla J; Kashefiolasl S; Noack A; Tichy J; Seifert V; Marquardt G
Clin Neurol Neurosurg; 2017 Oct; 161():22-28. PubMed ID: 28837843
[TBL] [Abstract][Full Text] [Related]
27. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
28. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
[TBL] [Abstract][Full Text] [Related]
29. Results from a first-in-human phase I safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.
Doron O; Wong T; Ablyazova F; Singha S; Cavallaro J; Ben-Shalom N; D'Amico RS; Harshan M; McKeown A; Zlochower A; Langer DJ; Boockvar JA
J Neurooncol; 2024 Jun; 168(2):225-235. PubMed ID: 38664311
[TBL] [Abstract][Full Text] [Related]
30. Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes.
Mampre D; Ehresman J; Pinilla-Monsalve G; Osorio MAG; Olivi A; Quinones-Hinojosa A; Chaichana KL
Br J Neurosurg; 2018 Oct; 32(5):528-535. PubMed ID: 30073866
[TBL] [Abstract][Full Text] [Related]
31. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
[TBL] [Abstract][Full Text] [Related]
32. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Arita H; Yamasaki K; Matsushita Y; Nakamura T; Shimokawa A; Takami H; Tanaka S; Mukasa A; Shirahata M; Shimizu S; Suzuki K; Saito K; Kobayashi K; Higuchi F; Uzuka T; Otani R; Tamura K; Sumita K; Ohno M; Miyakita Y; Kagawa N; Hashimoto N; Hatae R; Yoshimoto K; Shinojima N; Nakamura H; Kanemura Y; Okita Y; Kinoshita M; Ishibashi K; Shofuda T; Kodama Y; Mori K; Tomogane Y; Fukai J; Fujita K; Terakawa Y; Tsuyuguchi N; Moriuchi S; Nonaka M; Suzuki H; Shibuya M; Maehara T; Saito N; Nagane M; Kawahara N; Ueki K; Yoshimine T; Miyaoka E; Nishikawa R; Komori T; Narita Y; Ichimura K
Acta Neuropathol Commun; 2016 Aug; 4(1):79. PubMed ID: 27503138
[TBL] [Abstract][Full Text] [Related]
33. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
Drexler R; Schüller U; Eckhardt A; Filipski K; Hartung TI; Harter PN; Divé I; Forster MT; Czabanka M; Jelgersma C; Onken J; Vajkoczy P; Capper D; Siewert C; Sauvigny T; Lamszus K; Westphal M; Dührsen L; Ricklefs FL
Neuro Oncol; 2023 Feb; 25(2):315-325. PubMed ID: 35868257
[TBL] [Abstract][Full Text] [Related]
35. Pseudoprogression in glioblastoma patients: the impact of extent of resection.
Park HH; Roh TH; Kang SG; Kim EH; Hong CK; Kim SH; Ahn SS; Lee SK; Choi HJ; Cho J; Kim SH; Lee KS; Suh CO; Chang JH
J Neurooncol; 2016 Feb; 126(3):559-66. PubMed ID: 26608521
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
[TBL] [Abstract][Full Text] [Related]
37. Impact of extent of resection on outcome from glioblastoma using the RANO resect group classification system: a retrospective, population-based cohort study.
Bjorland LS; Mahesparan R; Fluge Ø; Gilje B; Dæhli Kurz K; Farbu E
Neurooncol Adv; 2023; 5(1):vdad126. PubMed ID: 37868696
[TBL] [Abstract][Full Text] [Related]
38. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
39. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
40. Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma.
Ahmadipour Y; Kaur M; Pierscianek D; Gembruch O; Oppong MD; Mueller O; Jabbarli R; Glas M; Sure U; El Hindy N
J Neurol Surg A Cent Eur Neurosurg; 2019 Jul; 80(4):262-268. PubMed ID: 30965373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
